Skip to Content

Institute for Applied Cancer Science

News and Media

The Institute for Applied Cancer Science, officially launched on Nov. 28, 2011, enhances and complements many other programs at MD Anderson, spanning basic, translational and clinical research. It also serves to foster collaborative interactions with pharmaceutical industry research and development groups.

Explore press releases about the Institute and our achievements: 

Agilent Technologies Thought Leader Award Supports Dr. Ronald A. DePinho and Translational Research Program at MD Anderson Cancer Center

UT MD Anderson and GlaxoSmithKline to collaborate on new approach to cancer immune therapy; success could earn cancer center $335 million plus royalties

Belfer gift creates consortium targeting neurodegenerative diseases

Institute of Medicine Elects Lynda Chin to Membership

Institute to Enable Drug Discovery and Development Platform of Unprecedented Moon Shots Program 

Drug combination against NRAS-mutant melanoma discovered

Institute Brings New Hope for Better Cancer Drugs

New Institute to Accelerate Cancer Drug Development

 

Learn more about the Institute 

Giulio Draetta Discusses the Advantages of the Institute's Approach

Lynda Chin Discusses the Work of the Institute

Institute Leaders Discuss Mission and Goals

Announcement of the Institute for Applied Cancer Science


© 2013 The University of Texas MD Anderson Cancer Center